WHO WE ARE
Oncofibro is a commercial-stage company developing advanced therapies for companion animals and a late-stage clinical development company focused on human health. Our current pipeline includes Krysaygio™, a first-in-class, autologous ex vivo T Cell therapy undergoing clinical evaluation.
Our lead assets are built on pioneering research in MYC biology and fusion protein engineering, developed by our co-founder Dr Yosef Rafaeli. These innovations were initially developed and patented under Invictus Biotech Solutions (formerly Taiga Biotechnology).
Our Name
Oncofibro is a portmanteau of two words representing our focus on developing first-in-class modalities for Oncology and Fibrosis. We are targeting oncology in both humans and companion animals. We take a platform approach with our focusin humans specific to lung diseases.
OUR APPROACH
Our focus on treating diseases in animals first is in line with our One World. One Health. approach.
COMMITMENT TO PATIENTS
Helping patients suffering from lung diseases is core to our mission.
Our Team
Management
Co-Founder/ Chairman &
interim CEO:
XL Lin
Co-Founder/ Chief Medical Officer
(CMO):
Yosef Rafaeli
Co-Founder/ Chief Scientific
Officer (CSO):
Dr. Brian C. Turner
© Oncofibro 2025. All rights reserved.